John Harris to Vitiligo
This is a "connection" page, showing publications John Harris has written about Vitiligo.
Connection Strength
26.625
-
Ezzedine K, Tannous R, Pearson TF, Harris JE. Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity. J Clin Invest. 2025 Jan 16; 135(2).
Score: 0.811
-
Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024 Apr; 113(4):156-158.
Score: 0.768
-
Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, S?gaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yildiz-Altay ?, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nat Commun. 2023 11 04; 14(1):7099.
Score: 0.746
-
Pearson TF, Harris JE. Expanding the White Armor of Vitiligo. J Invest Dermatol. 2024 01; 144(1):5-7.
Score: 0.743
-
Refat MA, Strassner JP, Frisoli ML, Rashighi M, Richmond J, Nada E, Saleh R, El-Hamd MA, Goldberg D, Mahmoud BH, Harris JE. Lesional CD8+ T-Cell Number Predicts Surgical Outcomes of Melanocyte-Keratinocyte Transplantation Surgery for Vitiligo. J Invest Dermatol. 2023 11; 143(11):2275-2282.e6.
Score: 0.731
-
Hsueh YC, Wang Y, Riding RL, Catalano DE, Lu YJ, Richmond JM, Siegel DL, Rusckowski M, Stanley JR, Harris JE. A Keratinocyte-Tethered Biologic Enables Location-Precise Treatment in Mouse Vitiligo. J Invest Dermatol. 2022 12; 142(12):3294-3303.
Score: 0.680
-
Essien KI, Katz EL, Strassner JP, Harris JE. Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo. J Invest Dermatol. 2022 12; 142(12):3158-3166.e7.
Score: 0.680
-
Gellatly KJ, Strassner JP, Essien K, Refat MA, Murphy RL, Coffin-Schmitt A, Pandya AG, Tovar-Garza A, Frisoli ML, Fan X, Ding X, Kim EE, Abbas Z, McDonel P, Garber M, Harris JE. scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function. Sci Transl Med. 2021 Sep 08; 13(610):eabd8995.
Score: 0.643
-
Rodrigues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Australas J Dermatol. 2021 08; 62(3):e481-e482.
Score: 0.630
-
Okamura K, Garber M, Harris JE. Gaining Insight into Vitiligo Genetics through the Lens of a Large Epidemiologic Study. J Invest Dermatol. 2021 04; 141(4):718-721.
Score: 0.624
-
Katz EL, Harris JE. Translational Research in Vitiligo. Front Immunol. 2021; 12:624517.
Score: 0.620
-
Rosmarin D, Butler K, Kuo F, Harris JE. Ruxolitinib cream for the treatment of vitiligo - Authors' reply. Lancet. 2020 11 28; 396(10264):1736.
Score: 0.609
-
Riding RL, Richmond JM, Fukuda K, Harris JE. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. Pigment Cell Melanoma Res. 2021 07; 34(4):683-695.
Score: 0.605
-
Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 07 11; 396(10244):110-120.
Score: 0.593
-
Azzolino V, Zapata L, Garg M, Gjoni M, Riding RL, Strassner JP, Richmond JM, Harris JE. Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells. J Invest Dermatol. 2021 01; 141(1):182-184.e1.
Score: 0.588
-
Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 04 26; 38:621-648.
Score: 0.576
-
Riding RL, Harris JE. The Role of Memory CD8+ T Cells in Vitiligo. J Immunol. 2019 07 01; 203(1):11-19.
Score: 0.552
-
Tkachenko E, Refat MA, Balzano T, Maloney ME, Harris JE. Patient satisfaction and physician productivity in shared medical appointments for vitiligo. J Am Acad Dermatol. 2019 Nov; 81(5):1150-1156.
Score: 0.542
-
Frisoli ML, Harris JE. Treatment with Modified Heat Shock Protein Repigments Vitiligo Lesions in Sinclair Swine. J Invest Dermatol. 2018 12; 138(12):2505-2506.
Score: 0.531
-
Richmond JM, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, Harris JE. Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. J Invest Dermatol. 2019 04; 139(4):769-778.
Score: 0.528
-
Riding RL, Richmond JM, Harris JE. Mouse Model for Human Vitiligo. Curr Protoc Immunol. 2019 02; 124(1):e63.
Score: 0.524
-
Richmond JM, Strassner JP, Zapata L, Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, Harris JE. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018 07 18; 10(450).
Score: 0.517
-
Fukuda K, Harris JE. Vitiligo-like depigmentation in patients receiving programmed cell death-1 inhibitor reflects active vitiligo. J Am Acad Dermatol. 2018 01; 78(1):e15-e16.
Score: 0.498
-
Frisoli ML, Harris JE. Vitiligo: Mechanistic insights lead to novel treatments. J Allergy Clin Immunol. 2017 Sep; 140(3):654-662.
Score: 0.484
-
Harris JE. Chemical-Induced Vitiligo. Dermatol Clin. 2017 Apr; 35(2):151-161.
Score: 0.473
-
Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr; 35(2):257-265.
Score: 0.473
-
Harris JE. Optimizing Vitiligo Management: Past, Present, and Future. Dermatol Clin. 2017 Apr; 35(2):xi.
Score: 0.473
-
Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017 May; 76(5):847-855.e5.
Score: 0.470
-
Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE. CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. J Invest Dermatol. 2017 04; 137(4):982-985.
Score: 0.467
-
Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017 Jan; 76(1):150-151.e3.
Score: 0.465
-
Rashighi M, Harris JE. Sampling Serum in Patients With Vitiligo to Measure Disease Activity in the Skin. JAMA Dermatol. 2016 11 01; 152(11):1187-1188.
Score: 0.459
-
Strassner JP, Harris JE. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol. 2016 12; 43:81-88.
Score: 0.458
-
Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J Invest Dermatol. 2017 02; 137(2):350-358.
Score: 0.456
-
Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016 08; 28(4):463-9.
Score: 0.451
-
Rashighi M, Harris JE. Serum chemokines herald disease activity and treatment response in vitiligo patients. Br J Dermatol. 2016 Jun; 174(6):1190-1.
Score: 0.446
-
Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016 Jan; 269(1):11-25.
Score: 0.433
-
Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016 Feb; 74(2):370-1.
Score: 0.432
-
Harris JE. Melanocyte Regeneration in Vitiligo Requires WNT beneath their Wings. J Invest Dermatol. 2015 Dec; 135(12):2921-2923.
Score: 0.431
-
Harris JE. IFN-? in Vitiligo, Is It the Fuel or the Fire? Acta Derm Venereol. 2015 Jul; 95(6):643-4.
Score: 0.419
-
Agarwal P, Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki-Toroudi H, Hunter CA, Harris JE. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol. 2015 Apr; 135(4):1080-1088.
Score: 0.403
-
Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014 Feb 12; 6(223):223ra23.
Score: 0.380
-
Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013 Dec; 22(12):785-9.
Score: 0.375
-
Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013 Dec; 25(6):676-82.
Score: 0.374
-
Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-? for autoreactive CD8? T-cell accumulation in the skin. J Invest Dermatol. 2012 Jul; 132(7):1869-76.
Score: 0.331
-
Hamzavi IH, Bibeau K, Grimes P, Harris JE, van Geel N, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Ren H, Ezzedine K. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol. 2023 10 25; 189(5):569-577.
Score: 0.186
-
Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Lindley A, Ren H, Hamzavi IH. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study. JAMA Dermatol. 2023 10 01; 159(10):1124-1128.
Score: 0.185
-
Seneschal J, Speeckaert R, Ta?eb A, Wolkerstorfer A, Passeron T, Pandya AG, Lim HW, Ezzedine K, Zhou Y, Xiang F, Thng S, Tanemura A, Suzuki T, Rosmarin D, Rodrigues M, Raboobee N, Pliszewski G, Parsad D, Oiso N, Monteiro P, Meurant JM, Maquignon N, Lui H, Le Poole C, Leone G, Lee AY, Lan E, Katayama I, Huggins R, Oh SH, Harris JE, Hamzavi IH, Gupta S, Grimes P, Goh BK, Ghia D, Esmat S, Eleftheriadou V, B?hm M, Benzekri L, Bekkenk M, Bae JM, Alomar A, Abdallah M, Picardo M, van Geel N. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023 Nov; 37(11):2185-2195.
Score: 0.185
-
Ren H, Akabane AL, Kelleher K, Halverstam C, Hicks M, Schachter JR, Silverman R, Chachkin S, Sherman-Bergman S, Harris JE, Kuohung V. Vitiligo induced by dupilumab treatment: A case series. J Eur Acad Dermatol Venereol. 2023 11; 37(11):2259-2261.
Score: 0.180
-
Garza-Mayers AC, Paquette GM, Harris JE, Wiss K. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study. J Am Acad Dermatol. 2023 07; 89(1):135-136.
Score: 0.178
-
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Tha?i D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2023 02; 88(2):395-403.
Score: 0.174
-
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 10 20; 387(16):1445-1455.
Score: 0.174
-
Pandya AG, Harris JE, Lebwohl M, Hamzavi IH, Butler K, Kuo FI, Wei S, Rosmarin D. Addition of Narrow-Band UVB Phototherapy to?Ruxolitinib Cream in Patients With Vitiligo. J Invest Dermatol. 2022 12; 142(12):3352-3355.e4.
Score: 0.170
-
Fatima S, Abbas T, Refat MA, Harris JE, Lim HW, Hamzavi IH, Mohammad TF. Systemic therapies in vitiligo: a review. Int J Dermatol. 2023 Mar; 62(3):279-289.
Score: 0.165
-
Seneschal J, Harris JE, Le Poole IC, Passeron T, Speeckaert R, Boniface K. Editorial: Immunology of Vitiligo. Front Immunol. 2021; 12:711080.
Score: 0.158
-
Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol. 2022 06; 86(6):1398-1401.
Score: 0.158
-
Lyons AB, Ghia D, Abdallah M, Abdel-Malek Z, Esmat S, Ezzedine K, Grimes P, Harris JE, Lui H, Manga P, Mi QS, Pandya A, Parsad D, Passeron T, Picardo M, Seneschal J, Silpa-Archa N, Taieb A, Xiang F, Lim HW, Hamzavi IH. Proceeding Report of the Second Vitiligo International Symposium-November 9-10, 2018, Detroit, Michigan, USA. Pigment Cell Melanoma Res. 2020 07; 33(4):637-641.
Score: 0.145
-
van Geel N, Hamzavi I, Kohli I, Wolkerstorfer A, Lim HW, Bae JM, Lui H, Harris JE, Pandya AG, Thng Tien Guan S, Abdallah M, Esmat S, Seneschal J, Speeckaert R, Grine L, Kang HY, Raboobee N, Xiang LF, Bekkenk M, Picardo M, Taieb A. Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. J Am Acad Dermatol. 2020 Dec; 83(6):1639-1646.
Score: 0.141
-
van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Flora Xiang L, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R. Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell Melanoma Res. 2019 09; 32(5):728-733.
Score: 0.137
-
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
Score: 0.121
-
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017 Jul; 77(1):1-13.
Score: 0.120
-
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017 Jul; 77(1):17-29.
Score: 0.120
-
Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, Esmat SM. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol. 2017 May; 76(5):879-888.
Score: 0.117
-
Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, Pandya AG. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015 Nov; 73(5):883-5.
Score: 0.107
-
Wu S, Li WQ, Cho E, Harris JE, Speizer F, Qureshi AA. Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell Melanoma Res. 2015 Nov; 28(6):744-6.
Score: 0.106
-
Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A. Vitiligo. Nat Rev Dis Primers. 2015 06 04; 1:15011.
Score: 0.104